Can we finally cure joint pain without trade-offs for risk? AlzeCure’s new ACD137 data point to a paradigm shift in osteoarthritis care.
What if treating chronic joint pain didn’t require a choice between efficacy and long-term harm? That’s the question at the heart of a new scientific publication from a Swedish biotech company AlzeCure Pharmawho discovered preclinical data on the lead pain candidate ACD137, a compound designed to target osteoarthritis pain via a non-opioid pathway (1).
The findings are published in the journal Scandinavian Journal of Painare not a complete cure. Instead, they map out a possible reprogramming of how pain itself is managed at a biological level. For osteoarthritis, a condition that affects hundreds of millions worldwide, change is more important than it might first appear.
To understand ACD137, it helps to step away from laboratory lingo for a moment. Pain in osteoarthritis isn’t just “wear and tear.” It’s more like a false alarm system that rings even when the original trigger has long passed. One of the biological pathways involved in the nervous system is NGF (nerve growth factor), which activates a receptor called TrkA.
ACD137 works by selectively modulating that TrkA receptor, essentially softening the signal rather than shutting down the entire system. Think of it like adjusting the sensitivity of a smoke detector so it doesn’t go off every time you bake.
The study describes ACD137 as highly selective and potent in preclinical models, meaning it strongly interacts with its intended target and largely avoids others, a key factor in reducing side effects (2).
What distinguishes the findings is not just the reduction in pain, but what happened alongside it. In animal models, ACD137 not only reduced pain behavior. It also showed signs of protecting the knee joint from further deterioration, something the researchers did not see with the anti-NGF antibody used as a comparator in the study.
Most pain treatments focus on symptom control. They turn off the alarm, but they don’t necessarily fix what’s causing the system to crash in the first place. A therapist who can also slow its deterioration blurs the line between symptom relief and disease modification. This is early information, yes, but directionally important.
The development of NGF-mediated pain medications has a complicated history. Previous treatments such as tanezumab have shown significant pain relief in clinical trials, but have raised concerns about joint safety, including rapidly progressing osteoarthritis in some patients. This history has made many developers wary.
But ACD137 represents a different strategy: instead of broadly blocking NGF activity, it regulates signaling through TrkA.
In studies, this compound has shown analgesic effects in a number of pain models, including neuropathic pain and osteoarthritis-like conditions. In comparative testing, its pain-relieving effects are similar to established treatments used in research models.
For researchers, the main question is no longer just “does it work?” but “can it work safely over time?” That’s where the selection becomes more than a technical detail; it becomes the difference between acceptable therapy and another cautionary tale.
The urgency of this research is not abstract. “There is great and growing interest in our TrkA-NAM program among external stakeholders, especially since the mechanism of action has not shown side effects and addiction problems with opioids. In addition, the medical need is very large and growing,” said Martin Jonsson, CEO of AlzeCure Pharma.
The need is amazing. The company cites estimates that more than 600 million people worldwide live with painful osteoarthritis, with the number increasing as the population ages. While opioid-based treatments have historically filled parts of this gap, their risks have shaped global expectations about how to manage pain. The future being explored here is not just about stronger painkillers. It’s about safety, not creating new public health crises in the process.
Osteoarthritis is often seen as a condition of aging – something inevitable, mechanical, almost taken for granted. This is changing now. Increasingly, longevity science is asking another question: What if aging-related decline was not just something to control, but something to intervene earlier and more precisely?
Seen through this lens, ACD137 is not just a pain compound. It is part of a broader category of research that focuses on maintaining function, joint preservation, mobility and independence for the long term.
This may sound ambitious for a preclinical study, and it is, but most changes in medicine begin with directional evidence that challenges default assumptions. Currently, ACD137 remains in the pre-clinical stage. It has not been tested in humans, and many questions remain about its safety, durability, and real-world effectiveness. However, the publication itself indicates that NGF pain research is still developing.
There is a subtle possibility in this evolution not only to eliminate pain, but also to change the shape of the body’s pain system as people age. If future studies confirm what these early data suggest, osteoarthritis treatment may move from managing decline to slowing it, and from temporary relief to something closer to long-term maintenance.
Featured in the main photo (right) are AlzeCure Pharma CEO Martin Johnson and Discovery Founder and CEO Pontus Forsell. Courtesy of AlzeCure.
(1) https://www.alzecurepharma.se/en/new-scientific-article-published-on-trka-nam-acd137-against-osteoarthritic-pain/
(2) https://www.degruyterbrill.com/document/doi/10.1515/sjpain-2026-0007/html
